Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 1Metastatic Pancreatic Adenocarcinoma 1

Interventions

Gemcitabine 5Irinotecan 2Albumin-Bound Paclitaxel 2regorafenib 1pembrolizumab 1olaparib 1ibrutinib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 14-fluorobenzoyl-TN-14003 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Pancreatic Adenocarcinoma × BKT140 × Clear all
NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡